# A Study of Bemarituzumab Monotherapy and Combination With Other Anti-cancer Therapy in SqNSCLC With FGFR2b Overexpression (FORTITUDE-201)

> **NCT05267470** · PHASE1 · TERMINATED · sponsor: **Amgen** · enrollment: 74 (actual)

## Conditions studied

- Squamous-Cell Non-Small-Cell Lung Cancer

## Interventions

- **DRUG:** Bemarituzumab
- **DRUG:** Docetaxel
- **DRUG:** Pembrolizumab
- **DRUG:** Carboplatin
- **DRUG:** Paclitaxel
- **DRUG:** Nab-paclitaxel

## Key facts

- **NCT ID:** NCT05267470
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-03-29
- **Primary completion:** 2024-05-28
- **Final completion:** 2024-05-28
- **Target enrollment:** 74 (ACTUAL)
- **Why stopped:** Business decision not due to safety concerns
- **Last updated:** 2025-03-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05267470

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05267470, "A Study of Bemarituzumab Monotherapy and Combination With Other Anti-cancer Therapy in SqNSCLC With FGFR2b Overexpression (FORTITUDE-201)". Retrieved via MORVS 2026-10-15 from https://api.morvs.ai/clinical/NCT05267470. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*